Research

Hormonal

GIPR antagonism reduces body weight in preclinical models by restoring leptin sensitivity, thereby reducing appetite.

Blocking GIP receptors can help obese individuals lose weight by making their bodies more sensitive to leptin, the hormone that signals fullness. This is currently only proven in animal models.

ModerateSupportsMEDIUM confidence
Kaneko et al, when investigating the effects of central infusion of Gipg013, proposed that the reason for the observed reduction in appetite was an improvement in leptin sensitivity.
Iona Davies et al. · Expert Opinion on Drug Discovery · 2023

Why this rating

Supported by specific preclinical studies, but human translation is unclear.

Source

Design of novel therapeutics targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) to aid weight loss

Iona Davies et al. · Expert Opinion on Drug Discovery · 2023

DOI 10.1080/17460441.2023.2203911

narrative_reviewCited 8×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →